The DOI matches its Crossref record.
Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months
Open accessAbstract
AIMS: To assess observations with multimodality imaging of the Absorb bioresorbable everolimus-eluting vascular scaffold performed in two consecutive cohorts of patients who were serially investigated either at 6 and 24 months or at 12 and 36 months. METHODS AND RESULTS: In the ABSORB multicentre single-arm trial, 45 patients (cohort B1) and 56 patients (cohort B2) underwent serial invasive imaging, specifically quantitative coronary angiography (QCA), intravascular ultrasound (IVUS), radiofrequency backscattering (IVUS-VH) and optical coherence tomography (OCT). Between one and three years, late luminal loss remained unchanged (6 months: 0.19 mm, 1 year: 0.27 mm, 2 years: 0.27 mm, 3 years: 0.29 mm) and the in-segment angiographic restenosis rate for the entire cohort B (n=101) at three years was 6%. On IVUS, mean lumen, scaffold, plaque and vessel area showed enlargement up to two years. Mean lumen and scaffold area remained stable between two and three years whereas significant reduction in plaque behind the struts occurred with a trend toward adaptive restrictive remodelling of EEM. Hyperechogenicity of the vessel wall, a surrogate of the bioresorption process, decreased from 23.1% to 10.4% with a reduction of radiofrequency backscattering for dense calcium and necrotic core. At three years, the count of strut cores detected on OCT increased significantly, probably reflecting the dismantling of the scaffold; 98% of struts were covered. In the entire cohort B (n=101), the three-year major adverse cardiac event rate was 10.0% without any scaffold thrombosis. CONCLUSIONS: The current investigation demonstrated the dynamics of vessel wall changes after implantation of a bioresorbable scaffold, resulting at three years in stable luminal dimensions, a low restenosis rate and a low clinical major adverse cardiac events rate. CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov/ct2/show/NCT00856856.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease
Ellis, S. G., Kereiakes, D. J., Metzger, D. C., Caputo, R. P., Rizik, D. G., Teirstein, P. S., Litt, M. R., Kini, A., Kabour, A., Marx, S. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509038 · Cited by 630
Serruys, P. W., Chevalier, B., Dudek, D., Cequier, A., Carrié, D., Iniguez, A., Dominici, M., van der Schaaf, R. J., Haude, M., Wasungu, L., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61455-0 · Cited by 564
Self-citationSerruys, P. W., Chevalier, B., Sotomi, Y., Cequier, A., Carrié, D., Piek, J. J., Van Boven, A. J., Dominici, M., Dudek, D., McClean, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32050-5 · Cited by 541
Self-citationCassese, S., Byrne, R. A., Ndrepepa, G., Kufner, S., Wiebe, J., Repp, J., Schunkert, H., Fusaro, M., Kimura, T., & Kastrati, A. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00979-4 · Cited by 369
Haude, M., Ince, H., Abizaid, A., Toelg, R., Lemos, P. A., von Birgelen, C., Christiansen, E. H., Wijns, W., Neumann, F.-J., Kaiser, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00447-x · Cited by 349
Self-citation
Metadata
- Authors
- Serruys, P. W., Onuma, Y., Garcia-Garcia, H. M., Muramatsu, T., van Geuns, R.-J., de Bruyne, B., Dudek, D., Thuesen, L., Smits, P. C., Chevalier, B., McClean, D., Koolen, J., Windecker, S., Whitbourn, R., Meredith, I., Dorange, C., Veldhof, S., Hebert, K. M., Rapoza, R., & Ormiston, J. A.
- Venue
- EuroIntervention
- Publisher
- Europa Digital & Publishing
- Published
- 2014-02
- Volume
- 9
- Issue
- 11
- Pages
- 1271-1284
- ISSN
- 1774-024X (ISSN-L)
- OpenAlex
- W1975007074
- Cited by
- 239
- References
- 0
- FWCI
- 52.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. https://app.cochat.ai/papers/10.4244/eijv9i11a217
- The paper
- Serruys, P. W., Onuma, Y., Garcia-Garcia, H. M., Muramatsu, T., van Geuns, R.-J., de Bruyne, B., Dudek, D., Thuesen, L., Smits, P. C., Chevalier, B., McClean, D., Koolen, J., Windecker, S., Whitbourn, R., Meredith, I., Dorange, C., Veldhof, S., Hebert, K. M., Rapoza, R., & Ormiston, J. A. (2014). Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. https://doi.org/10.4244/eijv9i11a217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.